Advertisement

Topics

Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

19:00 EST 18 Feb 2019 | Globe Newswire

DUBLIN, Ireland and CHICAGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today announced its participation at the SVB Leerink Partners Global Healthcare Conference.  The conference will be held from February 27- March 1 in New York. Corey Fishman, Chief Executive Officer, is scheduled to present an overview of the company on Thursday, February 28, 2019 at 10:30 a.m. ET.

An audio webcast of the presentation will be available in the Investors section of Iterum Therapeutics’ website at www.iterumtx.com under the Events and Presentations tab, with an archived replay available following the event.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound in Phase 3 clinical development with oral and IV formulations. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received QIDP designations for its oral and IV formulations for the treatment of uncomplicated urinary tract infection, complicated urinary tract infection and complicated intra-abdominal infection. For more information, please visit http://www.iterumtx.com.

Forward-looking Statements

This press release may contain forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem. In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum Therapeutics’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum Therapeutics’ control, including the uncertainties inherent in the initiation and conduct of clinical trials, clinical trial patient enrollment, availability and timing of data from clinical trials, changes in regulatory requirements or decisions of regulatory authorities, the actions of third-party clinical research organizations, suppliers and manufacturers, commercialization plans and timelines, if approved, and other factors discussed under the caption “Risk Factors” in its most recently filed Quarterly Report on Form 10-Q, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum Therapeutics’ beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum Therapeutics assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.  

Investor Contact:

Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com

Media Contact:

Claire La Cagnina
6 Degrees
315-765-1462
clacagnina@6degreespr.com 

Iterum Logo.jpg

NEXT ARTICLE

More From BioPortfolio on "Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...